Literature DB >> 20961664

Antemortem amyloid imaging and β-amyloid pathology in a case with dementia with Lewy bodies.

Kejal Kantarci1, Chunhui Yang, Julie A Schneider, Matthew L Senjem, Denise A Reyes, Val J Lowe, Lisa L Barnes, Neelum T Aggarwal, David A Bennett, Glenn E Smith, Ronald C Petersen, Clifford R Jack, Bradley F Boeve.   

Abstract

The association between ante mortem [(11)C]-Pittsburgh Compound B (PiB) retention and β-amyloid (Aβ) load, Lewy body (LB) and neurofibrillary tangle (NFT) densities were investigated in a pathologically confirmed case of dementia with Lewy bodies (DLB). A 76 year old man presenting with a clinical diagnosis of DLB had undergone PiB-positron emission tomography (PET), (18)F FDG-PET and magnetic resonance imaging (MRI) 18 months before death. The pathologic diagnosis was DLB neocortical-type with low-likelihood of Alzheimer's disease by NIA-Reagan criteria. Sections from regions of interest (ROI) on post-mortem examination were studied. A significant correlation was found between cortical Aβ density and PiB retention in the 17 corresponding ROIs (r = 0.899; p < 0.0001). Bielschowsky silver stain revealed mostly sparse neocortical neuritic plaques, whereas diffuse plaques were frequent. There was no correlation between LB density and PiB retention (r = 0.13; p = 0.66); nor between NFT density and PiB retention (r = -0.36; p = 0.17). The ROI-based analysis of imaging and histopathological data confirms that PiB uptake on PET is a specific marker for Aβ density, but cannot differentiate neuritic from diffuse amyloid plaques in this case with DLB. Copyright Â
© 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20961664      PMCID: PMC3026854          DOI: 10.1016/j.neurobiolaging.2010.08.007

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  38 in total

1.  [11C]PIB binding in Parkinson's disease dementia.

Authors:  Walter Maetzler; Matthias Reimold; Inga Liepelt; Christoph Solbach; Thomas Leyhe; Katherine Schweitzer; Gerhard W Eschweiler; Michel Mittelbronn; Alexandra Gaenslen; Michael Uebele; Gerald Reischl; Thomas Gasser; Hans-Jürgen Machulla; Roland Bares; Daniela Berg
Journal:  Neuroimage       Date:  2007-10-22       Impact factor: 6.556

2.  Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease.

Authors:  Joseph L Price; Daniel W McKeel; Virginia D Buckles; Catherine M Roe; Chengjie Xiong; Michael Grundman; Lawrence A Hansen; Ronald C Petersen; Joseph E Parisi; Dennis W Dickson; Charles D Smith; Daron G Davis; Frederick A Schmitt; William R Markesbery; Jeffrey Kaye; Roger Kurlan; Christine Hulette; Brenda F Kurland; Roger Higdon; Walter Kukull; John C Morris
Journal:  Neurobiol Aging       Date:  2009-04-18       Impact factor: 4.673

Review 3.  REM sleep behavior disorder: Updated review of the core features, the REM sleep behavior disorder-neurodegenerative disease association, evolving concepts, controversies, and future directions.

Authors:  Bradley F Boeve
Journal:  Ann N Y Acad Sci       Date:  2010-01       Impact factor: 5.691

4.  Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report.

Authors:  Nigel J Cairns; Milos D Ikonomovic; Tammie Benzinger; Martha Storandt; Anne M Fagan; Aarti R Shah; Lisa Taylor Reinwald; Deborah Carter; Angela Felton; David M Holtzman; Mark A Mintun; William E Klunk; John C Morris
Journal:  Arch Neurol       Date:  2009-12

5.  Comparison of 18F-FDG and PiB PET in cognitive impairment.

Authors:  Val J Lowe; Bradley J Kemp; Clifford R Jack; Matthew Senjem; Stephen Weigand; Maria Shiung; Glenn Smith; David Knopman; Bradley Boeve; Brian Mullan; Ronald C Petersen
Journal:  J Nucl Med       Date:  2009-05-14       Impact factor: 10.057

6.  Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography.

Authors:  P Edison; C C Rowe; J O Rinne; S Ng; I Ahmed; N Kemppainen; V L Villemagne; G O'Keefe; K Någren; K R Chaudhury; C L Masters; D J Brooks
Journal:  J Neurol Neurosurg Psychiatry       Date:  2008-07-24       Impact factor: 10.154

7.  11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment.

Authors:  Clifford R Jack; Val J Lowe; Matthew L Senjem; Stephen D Weigand; Bradley J Kemp; Maria M Shiung; David S Knopman; Bradley F Boeve; William E Klunk; Chester A Mathis; Ronald C Petersen
Journal:  Brain       Date:  2008-02-07       Impact factor: 13.501

8.  Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics.

Authors:  Walter Maetzler; Inga Liepelt; Matthias Reimold; Gerald Reischl; Christoph Solbach; Clemens Becker; Claudia Schulte; Thomas Leyhe; Stefanie Keller; Arthur Melms; Thomas Gasser; Daniela Berg
Journal:  Neurobiol Dis       Date:  2008-12-31       Impact factor: 5.996

9.  In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia.

Authors:  M A Burack; J Hartlein; H P Flores; L Taylor-Reinwald; J S Perlmutter; N J Cairns
Journal:  Neurology       Date:  2010-01-05       Impact factor: 9.910

10.  Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease.

Authors:  Milos D Ikonomovic; William E Klunk; Eric E Abrahamson; Chester A Mathis; Julie C Price; Nicholas D Tsopelas; Brian J Lopresti; Scott Ziolko; Wenzhu Bi; William R Paljug; Manik L Debnath; Caroline E Hope; Barbara A Isanski; Ronald L Hamilton; Steven T DeKosky
Journal:  Brain       Date:  2008-03-12       Impact factor: 13.501

View more
  52 in total

1.  Early AD pathology in a [C-11]PiB-negative case: a PiB-amyloid imaging, biochemical, and immunohistochemical study.

Authors:  Milos D Ikonomovic; Eric E Abrahamson; Julie C Price; Ronald L Hamilton; Chester A Mathis; William R Paljug; Manik L Debnath; Anne D Cohen; Katsuyoshi Mizukami; Steven T DeKosky; Oscar L Lopez; William E Klunk
Journal:  Acta Neuropathol       Date:  2012-01-24       Impact factor: 17.088

2.  Multimodality imaging characteristics of dementia with Lewy bodies.

Authors:  Kejal Kantarci; Val J Lowe; Bradley F Boeve; Stephen D Weigand; Matthew L Senjem; Scott A Przybelski; Dennis W Dickson; Joseph E Parisi; David S Knopman; Glenn E Smith; Tanis J Ferman; Ronald C Petersen; Clifford R Jack
Journal:  Neurobiol Aging       Date:  2011-10-21       Impact factor: 4.673

3.  Near-infrared fluorescence molecular imaging of amyloid beta species and monitoring therapy in animal models of Alzheimer's disease.

Authors:  Xueli Zhang; Yanli Tian; Can Zhang; Xiaoyu Tian; Alana W Ross; Robert D Moir; Hongbin Sun; Rudolph E Tanzi; Anna Moore; Chongzhao Ran
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-21       Impact factor: 11.205

4.  Neuroimaging correlates with neuropathologic schemes in neurodegenerative disease.

Authors:  Val J Lowe; Emily S Lundt; Sabrina M Albertson; Scott A Przybelski; Matthew L Senjem; Joseph E Parisi; Kejal Kantarci; Bradley Boeve; David T Jones; David Knopman; Clifford R Jack; Dennis W Dickson; Ronald C Petersen; Melissa E Murray
Journal:  Alzheimers Dement       Date:  2019-06-04       Impact factor: 21.566

Review 5.  Neuropathological correlates of amyloid PET imaging in Down syndrome.

Authors:  Eric E Abrahamson; Elizabeth Head; Ira T Lott; Benjamin L Handen; Elliott J Mufson; Bradley T Christian; William E Klunk; Milos D Ikonomovic
Journal:  Dev Neurobiol       Date:  2019-08-17       Impact factor: 3.964

Review 6.  Biomarkers for the Early Detection and Progression of Alzheimer's Disease.

Authors:  Scott E Counts; Milos D Ikonomovic; Natosha Mercado; Irving E Vega; Elliott J Mufson
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

7.  Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers.

Authors:  Clifford R Jack; David S Knopman; William J Jagust; Ronald C Petersen; Michael W Weiner; Paul S Aisen; Leslie M Shaw; Prashanthi Vemuri; Heather J Wiste; Stephen D Weigand; Timothy G Lesnick; Vernon S Pankratz; Michael C Donohue; John Q Trojanowski
Journal:  Lancet Neurol       Date:  2013-02       Impact factor: 44.182

8.  Imaging and acetylcholinesterase inhibitor response in dementia with Lewy bodies.

Authors:  Jonathan Graff-Radford; Bradley F Boeve; Otto Pedraza; Tanis J Ferman; Scott Przybelski; Timothy G Lesnick; Prashanthi Vemuri; Matthew L Senjem; Glenn E Smith; David S Knopman; Val Lowe; Clifford R Jack; Ronald C Petersen; Kejal Kantarci
Journal:  Brain       Date:  2012-07-18       Impact factor: 13.501

Review 9.  Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta.

Authors:  Ann D Cohen; Gil D Rabinovici; Chester A Mathis; William J Jagust; William E Klunk; Milos D Ikonomovic
Journal:  Adv Pharmacol       Date:  2012

10.  Amyloid-β deposition and regional grey matter atrophy rates in dementia with Lewy bodies.

Authors:  Lidia Sarro; Matthew L Senjem; Emily S Lundt; Scott A Przybelski; Timothy G Lesnick; Jonathan Graff-Radford; Bradley F Boeve; Val J Lowe; Tanis J Ferman; David S Knopman; Giancarlo Comi; Massimo Filippi; Ronald C Petersen; Clifford R Jack; Kejal Kantarci
Journal:  Brain       Date:  2016-07-24       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.